Hunson Kaz Soong

Hunson Kaz Soong

Auto-generated profile, based on publicly available information

Hunson Kaz Soong

Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, Michigan, USA

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
HSH. Kaz Soong
H. Kaz Soong
JMJoão Baptista Malta
João Baptista Malta

1 September 1990 in Ophthalmology
Verified
Journal Article
Closed access
TYTetsuya Yamamoto
Tetsuya Yamamoto
JVJames Varani
James Varani
HSH. Kaz Soong
H. Kaz Soong
PLPaul R. Lighter
Paul R. Lighter

1 May 1984 in Ophthalmology
Verified
Journal Article
Closed access
HSH. Kaz Soong
H. Kaz Soong
KKKenneth R. Kenyon
Kenneth R. Kenyon

1 January 2005 in Ophthalmology
Verified
Journal Article
Closed access
HSH Soong
H Soong
SMS Mian
S Mian
OAO Abbasi
O Abbasi
TJT Juhasz
T Juhasz

1 December 2014 in Cornea
Verified
Journal Article
Closed access
MHMunira Hussain
Munira Hussain
RSRoni M. Shtein
Roni M. Shtein
ASAlan Sugar
Alan Sugar
HSH. Kaz Soong
H. Kaz Soong
MWMaria Woodward
Maria Woodward
SMShahzad I. Mian
Shahzad I. Mian
The aim of this study was to describe the outcomes of 50% autologous serum (AS) eye drops after long-term use in a large cohort of patients with dry eyes. A retrospective cohort study was conducted on all patients treated with 50% AS eye drops at our institution between June 2008 and January 2013. Records were reviewed for clinical history, systemic risk factors, dry eye etiology, patients' symptoms, and adverse events. Ocular surface evaluation included Schirmer testing with topical anesthesia, fluorescein staining, and ocular surface disease index. Data were reviewed at initial visit, 1 month, and every 3 to 6 months during treatment with AS. Paired t tests were performed to compare the progression of signs and symptoms of dry eye disease. A total of 123 eyes of 63 patients were evaluated with a mean follow-up of 12 months (range, 3-48 months). Corneal fluorescein staining (mean baseline, 1.77 ± 1.1) improved at the 3- to <6-month, 6- to <12-month, and final follow-up (mean: 1.2 ± 1.0, 1.3 ± 1.0, and 1.1 ± 1.1; P = 0.003, 0.017, and 0.0003, respectively). Schirmer scores (mean baseline, 6.6 ± 6.5 mm) improved at the 12- to 24-month follow-up (mean = 10.7 ± 11.4, P = 0.03), whereas ocular surface disease index scores (mean baseline, 54.1 ± 22.3) improved at the 3- to <6- and 6- to <12-month follow-up (mean: 49.5 ± 8.2 and 39.3 ± 21.4, P = 0.029 and 0.003, respectively). No complications were noted. Fifty percent AS eye drops seem to be a safe and effective long-term treatment for dry eye disease, especially in patients with severe disease who have exhausted all other conventional forms of treatment.

1 May 1989 in Archives of Ophthalmology (1950)
Verified
Journal Article
Closed access
PDF file
HSH. Kaz Soong
H. Kaz Soong
DMDavid C. Musch
David C. Musch
VKVera Kowal
Vera Kowal
ASAlan Sugar
Alan Sugar
RMRoger F. Meyer
Roger F. Meyer
Research from JAMA Ophthalmology — Implantation of Posterior Chamber Intraocular Lenses in the Absence of Lens Capsule During Penetrating Keratoplasty